Short Interest in Clene Inc. (NASDAQ:CLNNW) Rises By 42.0%

Clene Inc. (NASDAQ:CLNNW) was the target of a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 7,100 shares, an increase of 42.0% from the September 30th total of 5,000 shares. Based on an average daily trading volume, of 7,000 shares, the short-interest ratio is presently 1.0 days.

Clene Trading Down 34.8 %

Shares of NASDAQ CLNNW traded down $0.02 during mid-day trading on Tuesday, hitting $0.03. The company had a trading volume of 7,600 shares, compared to its average volume of 10,807. The firm’s 50 day simple moving average is $0.04 and its two-hundred day simple moving average is $0.04. Clene has a 12 month low of $0.02 and a 12 month high of $0.09.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.